Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384347 | 1.00 | GPR119 (0.50) | GPR119POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL4319554 | 1.00 | GPR119 (0.50) | GPR119POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL18448499 | 0.82 | GSK3B (0.43) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3119867 | 0.82 | SLC6A7 (0.43) | — | |
| SCHEMBL5239428 | 0.81 | GPR119 (0.48) | GPR119POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL15024213 | 0.80 | GPR119 (0.61) | GPR119POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL124268 | 0.80 | POLB (0.60) | GPR119POLB | |
| SCHEMBL30592010 | 0.80 | POLB (0.60) | GPR119POLB | |
| SCHEMBL23426249 | 0.79 | SMARCA2 (0.45) | GPR119POLBSMARCA2SMARCA4PBRM1 | |
| SCHEMBL20154088 | 0.79 | SMARCA2 (0.45) | GPR119POLBSMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-8835439-B2 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases | PROXIMAGEN LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | BIOVITRUM AB (PUBL) (SE) | 2013-06-20 | — | — | US | disclosed |
| US-8410113-B2 | (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof | BIOVITRUM AB (PUBL) (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-12 | — | — | US | disclosed |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-05 | — | — | US | disclosed |
| US-8030316-B2 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine | BIOVITRUM AB (PUBL) (SE) | 2011-10-04 | — | — | US | disclosed |
| US-7820677-B2 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100256374-A1 | NOVEL PROCESS | BIOVITRUM AB, A SWEDEN CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060142578-A1 | Novel process | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-06-29 | — | — | US | disclosed |
| EP-1645558-A1 | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | BIOVITRUM AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040038981-A1 | Novel Process | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-26 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | GPR119 38/4885POLB 3747/4885SMARCA2 2556/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | GPR119 38/4885POLB 3863/4885SMARCA2 2684/4885 |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | SUCNR1, HTR5A, HTR2C | GPR119 877/4885POLB 3064/4885SMARCA2 2502/4885 |
| US-20100256374-A1 | NOVEL PROCESS | HTR1A, TPH1, HTR5A | GPR119 309/4885POLB 4102/4885SMARCA2 4190/4885 |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | HTR2C, HTR5A, HTR2A | GPR119 510/4885POLB 4536/4885SMARCA2 3885/4885 |
| US-20040038981-A1 | Novel Process | HTR1A, TPH1, HTR1B | GPR119 458/4885POLB 3876/4885SMARCA2 4572/4885 |
| US-20060142578-A1 | Novel process | HTR1A, TPH1, HTR5A | GPR119 290/4885POLB 3980/4885SMARCA2 4330/4885 |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | GPR119 510/4885POLB 4536/4885SMARCA2 3885/4885 |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | GPR119 510/4885POLB 4536/4885SMARCA2 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.